A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
Author:
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2005.05448.x/fullpdf
Reference22 articles.
1. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
2. Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
3. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
4. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group
5. Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting cellular senescence as a therapeutic vulnerability in gastric cancer;Life Sciences;2024-06
2. Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics;Vaccines;2021-01-27
3. Targeting androgen-independent pathways: new chances for patients with prostate cancer?;Critical Reviews in Oncology/Hematology;2017-10
4. cGMP-Dependent Protein Kinase Iβ Interacts with p44/WDR77 to Regulate Androgen Receptor-Driven Gene Expression;PLoS ONE;2013-06-03
5. Docetaxel-based combination therapy for castration-resistant prostate cancer;Annals of Oncology;2010-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3